DoD Peer Reviewed Orthopaedic Research Program Funding Opportunities

How to Apply: 

The FY22 Defense Appropriations Act is anticipated to provide funding for the PRORP to support high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

 

The FY22 PRORP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

 

Applications submitted to the FY22 PRORP must address one or more of the following Focus Areas:

 

  • Compartment Syndrome and/or Reperfusion Injury:  Novel treatment strategies to improve current diagnoses for compartment syndrome and/or reperfusion injury.  Proposals that address the novel treatment strategies to improve the management of reperfusion injury will be considered.  Alternatives to intracompartmental pressure measurements are encouraged.
  • Composite Tissue Regeneration:  Advanced tissue regeneration therapeutics in composite tissue for the restoration of traumatically injured extremities.  Isolated bone, cartilage, muscle, or nerve tissue engineering studies are excluded.  Techniques aimed at improving outcomes following high-energy extremity trauma, with a focus on improving wound healing and neuromuscular recovery following composite tissue loss and segmental bone loss, are encouraged.
  • Limb Stabilization and Protection:  Development and/or clinical evaluation of rapid limb stabilization and novel wound protectants for severely or critically wounded limbs to enable prolonged care and eventual transport to the point of definitive treatment.
  • ·        Osseointegration:  Identification of best practices to address infection, rejection, and/or failure of percutaneous osseointegrated prosthetic limbs.
  • ·        Prostheses and Orthoses:  Development of high-performance novel prosthetic or orthotic devices designed to enhance whole-person performance and decrease pain in patients with amputation and limb salvage and impairment.  Multicenter studies that focus on transfemoral amputees are encouraged, as are advanced limb orthoses that span at least one major joint (i.e., ankle, knee, and elbow).
  • ·        Retention Strategies:  Development, optimization, and/or validation of battlefield-feasible diagnostic capabilities, decision support tools, interventions, and/or rehabilitation strategies that can facilitate retention on duty or avoid reinjury for common combat-related musculoskeletal injuries.  Biomarker studies are excluded.  The current standard of care must be noted.  The rehabilitation strategy to be used in the proposed study must be specified, as applicable.

a. Battlefield Care:  Strategies that can be utilized at or near the point of injury to allow an injured Service Member to remain on the battlefield or on mission without the need for evacuation.  Development of novel nerve, soft tissue, muscle, and/or skeletal diagnostic capabilities at the point of injury (near battlefield) for diagnosis of underlying pathology and efficacy of interventions.  Treatment strategies that allow return to mission effectiveness within 30 days will be considered.

b. Return to Duty:  Treatment strategies that can be utilized along the continuum of care and enable return to duty of the Service Member within 1 year of injury.

  • ·        Tissue Regeneration Therapeutics:  Advanced tissue regeneration therapeutics in nerve, muscle, and/or composite tissue for the restoration of traumatically injured extremities.  Isolated bone or cartilage tissue engineering studies are excluded.  Early clinical feasibility studies involving volumetric muscle loss are encouraged.
  • Translation of Early Findings:  Translation of early research findings in the orthopaedic surgical care topic areas listed below to move the research toward clinical trials and clinical practice.

a. Soft Tissue Trauma:  Strategies to develop and/or identify musculoskeletal extremity soft tissue trauma treatments for shoulder, knee, or chronic ankle instability and sequela only to optimize return to duty, work, or reintegration.

b. Fracture-Related Infection:  Strategies to decrease the burden of fracture-related infections (may include prevention, early detection, or improved eradication).  Alternatives to systemic antibiotic delivery are encouraged.  Novel approaches that improve the current standard of treatment to prevent fracture-related infections are encouraged.

 

Funding Opportunities-FY22 PRORP, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

 

Applied Research Award – Preproposal due June 16, 2022

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

Supports applied research applications focused on advancing optimal treatment and restoration of function

for individuals with musculoskeletal injuries sustained during combat, combat-related activities, and non-battle

injuries that impact unit readiness and the ability to return to duty/work.

• Proposed research should be supported by preliminary and/or published data and have the potential to make

significant advancements toward clinical translation.

• Clinical research and clinical trials are not allowed under this award mechanism.

• Applications must address one of the following FY22 PRORP ARA Focus Areas: ○ Limb Stabilization

and Protection

○ Retention Strategies

− Battlefield Care

− Return to Duty

○ Osseointegration

○ Composite Tissue Regeneration

• Pre-application submission is required; application submission is by invitation only.

The maximum allowable funding for the entire period of performance is $725,000 for total costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is years.

 

Clinical Trial Award – Preproposal due June 16, 2022

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

Supports rapid implementation of clinical trials with the potential to have a significant impact on the treatment

or management of military combat-related orthopaedic injuries or non-battle injuries that significantly impact

unit readiness and return to duty/work rates.

• Funding must support a clinical trial and may not be used for animal or preclinical research studies.

• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted

to the Food and Drug Administration or relevant national regulatory agency within 6 months of the award date.

• Applications must address one of the following FY22 PRORP CTA Focus Areas:

○ Limb Stabilization and Protection

○ Retention Strategies

− Battlefield Care

− Return to Duty

○ Translation of Early Findings

− Soft Tissue Trauma

− Fracture-Related Infection

• All applications, regardless of the selected Focus Area, are eligible for Research Level 1.

• Applications submitted to address the Translation of Early Findings – Soft Tissue Trauma Focus Area and

include the Collaborative Care Option are eligible for Research Level 2.

• Pre-application submission is required; application submission is by invitation only.

Research Level 1:

• The maximum allowable funding for the entire period of performance is $2.5 million (M) for total costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is years.

Research Level 2:

• The maximum allowable funding for the entire period of performance is $3.0M for total costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is years.

 

Clinical Translational Research Award – Preproposal due June 16, 2022

Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

Supports high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial.

• Funding must support clinical research studies involving humans.

• Preliminary data relevant to the proposed research project are required.

• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration or relevant national regulatory agency within 12 months of the award date.

• Applications must address one of the following FY22 PRORP CTRA Focus Areas:

○ Retention Strategies − Battlefield Care

− Return to Duty

○ Tissue Regeneration Therapeutics

○ Compartment Syndrome and/or Reperfusion Injury

○ Osseointegration

○ Prostheses and Orthoses

• Pre-application submission is required; application submission is by invitation only.

The maximum allowable funding for the entire period of performance is $1.5M for total costs.

• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• The maximum period of performance is years.

 

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

Please contact Jill Sherman, International Research Facilitator at intl.research@lakeheadu.ca  for additional information.

External Deadline: 
Thursday, June 16, 2022
Funding Source: 
External
Funding Level: 
Research